Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That’s the strategy management laid out for investors during an R&D day in New York April 8.
You may also be interested in...
Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact
Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product